Back to Research Hub
Denali Therapeutics Inc.
DNLI
$22.49-0.36 (-1.58%)
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc.
StreetsValue research for Denali Therapeutics Inc. (DNLI)
Members get the full report for Denali Therapeutics Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.